Company
Genflow Biosciences Ltd
LON:GENF
Genflow Biosciences is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs, supporting longer, healthier lives. The company's lead compound, GF-1002 operates through the delivery of a centenarian variant of the SIRT6 gene. This gene, identified in individuals who reach the age of 100 or beyond, has demonstrated promising preclinical results.
90 stories · page 5 of 5
Genflow receives grant for anti-ageing project in Estonia
The programme is targeting patients who suffer from Werner’s syndrome, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Genflow Biosciences confident about future after string of collaborations
Net cash at the end of the half year to June 2022 was £2.95mln
Genflow adds 'capital markets experience' with board appointments
"The appointments will furnish the board with broad and relevant experience of US-listed biotech companies,” a statement said
Genflow Biosciences signs up research partner to accelerate therapeutic developments
Magnitude's innovative technology "has the capacity to significantly expedite product development, supported by sophisticated machine monitoring", said Genflow CEO Eric Leire
Genflow Biosciences files patent for gene treatment to ‘regulate aging’
It is based on a gene variant seen in centenarians, people over 100 years old
Genflow Biosciences says it has made 'excellent strategic' progress since float
The group, which is developing treatments that promote healthy long life, joined the market in January
Genflow Biosciences teams up with world leader in cellular ageing
It is working with France’s Organips, headed by professor Jean Marc Lemaitre, to initially research the Sirtuin-6, or SIRT6 gene variant found in centenarians
Genflow Biosciences inks collaboration agreement with US university aimed at reversing the ageing of liver tissue
It is teaming up with the University of Rochester's Aging Research Center, a leader in the field, and its principal, Dr Vera Gorbunova
Genflow Biosciences receives a grant of up to €3.375mln from the regional government of southern Belgium
Chief executive, Dr Eric Leire, said: "Access to non-dilutive public funding is highly prized and much sought-after"